Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging." (7/31/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James More >
Bryan Brokmeier, senior life science tools and diagnostics analyst, covers medical device, healthcare service and life science companies as a vice president of equity research at Maxim Group. Brokmeier has been with Maxim Group since 2009, when he joined as an associate analyst covering medical device, healthcare IT and service companies. Previously, he worked as an associate analyst at Credit Suisse and as a senior portfolio accountant at Brown Brothers Harriman. Brokmeier has been quoted in numerous financial publications, such as The Wall Street Journal, Barron's, Investor's Business Daily and Bloomberg News. He holds a master's degree in business administration (finance and accounting) from Indiana University's Kelley School of Business, and a bachelor's degree in finance and applied economics from Ithaca College. He is a CFA charterholder, and a member of the New York Society of Securities Analysts, the CFA Society of Chicago and the CFA Institute.
Bryan Brokmeier Remains Bullish on Life Sciences Tools and Diagnostics Companies (2/27/14) This will be a great year for life sciences tools and diagnostics companies, says Bryan Brokmeier of Maxim Group. And no, growth won't be driven by irrational exuberance, the senior analyst explains in this interview with The Life Sciences Report. Instead, the industry is bolstered by powerful tailwinds fanning new demand for molecular diagnostics, and by the clamoring of academia, pharmas and biotechs for specialized assay platforms. As Brokmeier lays out his sector growth theory, he also highlights a group of stocks with value drivers that could power a portfolio with biotechlike growth potential.
Global Expansion and Affordable Care Act Boost Life Science Tools and Diagnostics: Bryan Brokmeier (11/7/13) Two years ago, medtech was thought to be waning. Investors were deserting companies perceived to be short on margins and sure to be demolished by the Affordable Care Act. Today the landscape is transformed: Medtech companies are embracing international markets, preparing for increased volumes of procedures and enjoying new, rich valuations. Do they have what it takes to woo investors back? In this interview with The Life Sciences Report, Bryan Brokmeier of the Maxim Group picks a small group of names that have performed brilliantly over the past year and that he expects will treat investors very well.
"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino More >